Xonar Technology Inc. Names Paul Sarnese to Advisory Board
Xonar Technology Inc., developer of next-generation contactless security screening systems, has named Paul Sarnese, a leading healthcare security consultant, to the company's advisory board.
Sarnese joins prominent leaders and technology experts on Xonar®'s advisory board as the company launches its AI-empowered TruePort ® screening devices in sports venues and other facilities. Sarnese's experience will be pivotal as Xonar supports California healthcare facilities in complying with Assembly Bill 2975, which mandates the use of enhanced weapons-screening and threat detection devices in hospitals.
'Xonar is committed to delivering the most advanced, portable screening system to all sectors. With Paul joining our advisory board, Xonar welcomes a seasoned individual in the healthcare space highlighting our dedication to providing innovative security solutions to the hospital industry,' says Hans Hufschmid, Xonar's Chairman & Chief Executive Officer. 'We are very pleased to have Paul's expertise guiding us.'
With more than 25 years of experience as a security and safety executive, Paul is currently owner of Secured & Prepared Consulting, which has provided numerous companies with customized workplace violence, safety, security, emergency management, and regulatory compliance assessments. He is past president of the International Association of Hospital Security and Safety and is a sought-after speaker and author on workplace safety.
ABOUT XONAR TECHNOLOGY INC.
Xonar Technology Inc. is at the forefront of security screening innovation, blending advanced multi-sensor technology, cutting-edge image processing, AI, and cloud computing to minimize human error and maximize throughput and accuracy. Xonar offers two products: TruePort ®, a state-of-the-art multi-sensor screening technology using machine learning and artificial intelligence to discern threats from everyday items, regardless of metallic content; and TrueScan TM, an AI-empowered portable X-ray system. TruePort's multi-sensor technology preserves individual privacy and the dual built-in cameras allow for biometric authentication for streamlined ticketing and access control.
The Department of Homeland Security has designated Xonar TruePort as a Qualified Anti-Terrorism Technology under the SAFETY Act. The National Center for Spectator Sports and Security (NCS 4 ) evaluated Xonar TruePort's ability to detect concealed weapons. The evaluation matrix covered a wide range of functions, including weapon detection, speed of detection, placement detection, alerts, wireless interface, event reporting, outcome reporting, and user interface. The overall composite score of 2.93, out of a possible 3.00, showed that all capabilities were successfully demonstrated.
SOURCE: Xonar Technology Inc.
Copyright Business Wire 2025.
PUB: 03/03/2025 08:06 AM/DISC: 03/03/2025 08:06 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Yahoo
39 minutes ago
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Goldman Sachs wants students to stop using ChatGPT in job interviews with the bank
Goldman Sachs is cautioning its young job-seekers against using AI during the interview process. Instead, the $176 billion bank is encouraging applicants to study up on the firm in preparation. Other businesses like Anthropic and Amazon have also warned candidates against deploying AI—and if they're caught, they could be disqualified. While many companies are boasting about all the efficiencies that will come with AI, some are dissuading potential hires from using it to get a leg up in interviews with recruiters and hiring managers. Goldman Sachs' campus recruitment team for the bank's private investing academy in EMEA recently sent out an email to students reminding them of its expectations for interviews, as reported by eFinancialCareers. Goldman uses video interviewing platform HireVue to pre-assess candidates and maintains a set of best practices for job-seekers. Based on the best practices guidelines, the young applicants are encouraged to prepare for interviews by studying the $176 billion firm's financial results, business principles, and core values. But they can't bank on AI to help them out. 'As a reminder, Goldman Sachs prohibits the use of any external sources, including ChatGPT or Google search engine, during the interview process,' the email noted, according to someone who saw the message. HireVue is an AI-powered talent evaluation platform, known for asking behavioral questions that reveal applicants' skills. Gen Z job-seekers might be tempted to use ChatGPT or other chatbots to game the recruitment process—but it's discouraged, and isn't the most viable option. The typical Goldman Sachs virtual interview allows for 30 seconds of prep after the question, followed by a two-minute response time, according to research from eFinancialCareers. That makes it hard for job-seekers to quickly type a prompt into the chatbot, churn out an answer, and decide what the line of attack is. Plus, the responses aren't tailored and unique to the individual, potentially hurting the interviewee more than helping. Goldman's job-seeker AI policy could seem ironic, as half of the firm's 46,000 employees have access to the technology. But other companies are navigating that same paradox as they try to fully flesh out their AI strategies in an ever-changing technological environment. Goldman Sachs isn't the only major company warning its applicants not to use AI during recruitment. The $61.5 billion AI giant Anthropic went on a hiring spree last month, but told job-seekers that they can't use the advanced technology to fill out their applications. The company argued that it wants to test the communication skills of potential hires, and AI use clouds that assessment. 'Please do not use AI assistants during the application process,' Anthropic wrote in the description for its hundreds of job postings. 'We want to understand your personal interest in Anthropic without mediation through an AI system, and we also want to evaluate your non-AI-assisted communication skills.' Retail giant Amazon also doesn't like it when potential talent uses AI tools during the recruitment process. Earlier this year, the $2 trillion behemoth shared guidelines with internal recruiters, stressing that candidates who are caught using AI during job interviews should be disqualified. According to Amazon, the tools give an 'unfair advantage' that masks analysis of someone's 'authentic' capabilities. 'To ensure a fair and transparent recruitment process, please do not use gen Al tools during your interview unless explicitly permitted,' the guidelines, as reported by Business Insider, noted. 'Failure to adhere to these guidelines may result in disqualification from the recruitment process.' This story was originally featured on
